🟢 ACADIA Pharmaceuticals is trading 8.8% up in pre-market

ACADIA Pharmaceuticals is trading at $22.50, up 8.80% in pre-market, with no fresh catalyst established by the available evidence.

• No new September 28 company announcement surfaced in the search.
• The gain follows a steep selloff after September 24 Phase 2 RADIANT results narrowly missed the primary endpoint; the 60 mg dose met a key secondary measure.
• Needham, Deutsche Bank, BMO Capital and Citizens cut price targets after the trial update.